March 2018

London, UK

2017 Speakers


Drug Developers

Frederic Ausseil
Head of Companion Diagnostic Medical Platform
Pierre Fabre

Frederic  holds the role of Head of Companion Diagnostic Medical Platform at Pierre Fabre. He has worked at Pierre Fabre for the past 18 years, previously holding roles at Merck KGaA and bioMerieux. He gained his Masters degree in Biochemistry from the University of Montpellier in 1991, before getting his PhD in Biological and Medical Engineering from the Université Claude Bernard Lyon 1 in 1996.  

Katja Berg
Vice President, Head of Operations & Payer Intelligence
Global Market Access, Sanofi

Flora Berisha
Associate Director, Companion Diagnostics
Daiichi Sankyo

Flora Berisha is an Associate Director of Companion Diagnostics at Daiichi Sankyo Pharma. Flora received her BS in Biochemistry from University of Albania and MSS in Biology from City University of New York. She currently leads CDx development for multiple oncology projects. Prior to Daiichi Sankyo, Flora was at Kyowa Hakko Kirin Pharma as a Senior Manager. At KHK she focused on strategic biomarker selection, development and translation into CDx assays. She was the lead on representing CDx strategies to external partners and regulatory agencies. Prior to KHK, Flora was at Bristol-Myers Squibb where she progressed through the ranks gaining valuable experience in GLP and clinical Bioanalysis, biomarker assay development and validation, CDx assay development from design control through commercialization. In addition to Flora’s industry experience, she is currently an Adjunct Professor in the Department of Biology at City university of New York where she has been teaching anatomy-physiology and biology for over a decade.

Day One

29th March 2017

11.15 | Challenges in Developing Companion Diagnostics: Alignment with Stakeholders is the Key to Success

Franck Brichory
Associate Director, Personalized Medicine
Debiopharm International AG

Franck Brichory has a PhD in Cellular and Molecular Biology with more than 20 years of experience on biomarker research and development with a main focus in oncology. Franck spent the last 15 years in the pharmaceutical industry in various positions from biomarker discovery to the development of CDx. In his current position as Associate Director Personalized Medicine at Debiopharm International SA he contributes to the development of novel predictive biomarkers bringing together clinical, translational and basic research.

Ralph Graeser
Senior Translational Medicine Expert
Boehringer Ingelheim

Ralph received his PhD in Biochemistry at the University of Basel for his thesis on malarial CDK-like kinases. He continued to work on CDK-like kinases as a postdoc at the Imperial Cancer Research Fund (ICRF) in the lab of Nobel laureate Prof. Tim Hunt. Still following his interest in protein kinases he then joined ProQinase GmbH to support drug discovery and translational fee-for-service projects in Oncology. Applying his experience in oncology drug discovery/early development, he subsequently moved to Janssen and later to Böhringer Ingelheim to support the translation of Oncology programs to the clinic. In addition to working on biomarker strategies he has been involved in several IMI-projects, including the PREDECT program for which he acted as a co-coordinator.

Matthias Hackl

Dr. Matthias Hackl is the current CEO of TAmiRNA GmbH, which was founded in 2013 and is located in Vienna, Austria. Matthias holds a Ph.D. in biochemistry and molecular biology. Prior to co-founding TAmiRNA in 2013, he lead genomic research projects in academia, including fellowships at the University of Minnesota and University Bielefeld. He has several years of experience in biomarker development with a focus on non-coding RNA analysis in liquid biopsies. Within TAmiRNA he is currently preparing the clinical performance evaluation of microRNA biomarkers for patient stratification in osteoporosis and cardiovascular disease.

Liz Harrington
Director, Translational Science, Oncology

Frank Kramer
Director Biomarker Strategist, Experimental Medicine
Cardiovascular & Hematology, Bayer Pharma AG

Frank Kramer, Ph.D. is Director Biomarker Strategist in BAYER Pharma AG`s Experimental Medicine group in Wuppertal, Germany. In this role he develops and implements biomarker strategies in order to select and monitor patients in clinical studies. Furthermore, he manages the cardiovascular biomarker portfolio. Before taking over the current role Dr. Kramer worked as a lab head and identified targets and biomarkers in cardiovascular and pulmonary in-vitro and in-vivo models. Dr. Kramer held appointments at Wyeth, Aventis and Sanofi in Germany and Ireland in the past. He authored more than 30 peer reviewed publication and book chapters in the field of pre-clinical and clinical cardiology and biomarker research. Dr. Kramer obtained his Ph.D. at the University of Pharmacy in Frankfurt, Germany.

Day Two

30th March 2017

09.30 | Digital Transformation of Clinical Trials in Cardiovascular Indications: Utilising Medical Devices to Select Patients & Remotely Monitor Safety & Efficacy

Gereon Lauer
Associate Director, Discovery Biomarkers
Vertex Pharmaceuticals

Gereon Lauer has joined Vertex Pharmaceuticals in 2013 and is currently working as Associate Director Discovery Biomarkers. His responsibilities include the identification, validation and implementation of biomarkers for several therapeutic areas including oncology and neurodegenerative diseases. He also oversees external assay development activities for Vertex biomarker functions including the development of patient stratification tools. Dr. Lauer started his professional career at Byk Gulden/Altana Pharma where he was responsible for several early research projects in inflammation and respiratory diseases. In 2006 he started to work on clinical biomarkers and was overseeing biomarker identification studies for COPD and established a laboratory for the development of pharmacodynamics biomarkers. He was responsible for biomarker strategies of several development projects for rheumatoid arthritis and respiratory diseases. From 2010 he served as Head of the Biomarker development group at Nycomed. Dr. Lauer studied biology at the University in Düsseldorf and received a Ph. D. in Genetics from the University of Cologne.

Maria Orr
Executive Director, Personalised Healthcare & Biomarkers

Maria Orr graduated from Trinity College, Dublin and completed a PhD in molecular genetics at Sheffield University.  Following a brief period in academia, Maria moved into the pharmaceutical industry in 1994 where she has been actively involved in the application of genetics to drive drug discovery & development. Maria joined the oncology therapeutic area of AstraZeneca in 2005 where she championed of the use of biomarkers to aid clinical drug development, focusing primarily on the use of biomarkers to drive patient segmentation.  In 2010 she joined the newly formed Personalised Healthcare & Biomarkers (PHB) function of AZ where she successfully led the team delivering the companion diagnostic for the PARP inhibitor Lynparza (olaparib).  In April 2016 Maria moved to a Franchise Leader position in PHB where she oversees the delivery of companion diagnostics for the DNA Damage Response and EGFR portfolios for oncology.

Erin Pedalino
Associate Director, Regulatory Affairs International
Merck Sharp & Dohme Corp.

Erin Pedalino has nearly 20 years of experience in the pharmaceutical industry, of which the past 5 have been at Merck Sharp & Dohme Corp. As Associate Director in the Regulatory Affairs International (RAI) Department, she acts as regulatory liaison in collaboration with the Company’s diagnostics partners for the global registration of companion diagnostics for MSD’s products.  She focuses her time developing global registration strategies for integrated drug and diagnostic filings across Asia Pacific, Eastern Europe/Middle East/Africa, and Latin America.  Erin also has experience in CMC regulatory and as a RAI Therapeutic Area Liaison for pharmaceutical products, combination products and medical devices as well as technical experience in drug stability and analytical chemistry.  Erin’s academic background includes a BS in Chemistry from Lafayette College and an MS in Regulatory Affairs and Quality Assurance from Temple University.

Chaminda Salgado
Senior Investigator

I started my career in 1995 at the (then) Chemical and Biological Defence Establishment at Porton working in the Gene Probes group which were involved in developing portable technologies to detect Biological Weapons for the battlefield, weapons inspectorates and homeland securities. I then moved to Biopharm at GSK in 2000 where I initially setup, developed and ran CMCs qPCR facilities, for monitoring the process and potency measurements of drug products. I later lead efforts in electronic data integrity and early stage (lead candidate to clinic) project leadership for some DNA vaccine assets. In 2014 I joined Cell and Gene Therapies as a Medicinal Process Delivery Leader and had responsibilities leading the CMC effort in order to launch (clinic to commercialisation) Strimvelis, the first gene therapy for children. Strimvelis targets an ultra rare disease ADA-SCID (adenosine deaminase severe combined immunodeficiency) a form of bubble boy/baby syndrome, however for more common indications the current analytical capability would be a considerable bottleneck to address. So now in my current role the focus is to seek out solutions to resolve our current analytical challenges in preparation to commercialise Cell and Gene Therapy assets that will address more common indications.

Ranga Sarangarajan
Senior Vice President & CSO
Berg Health

Dr. Sarangarajan is the Senior Vice President & Chief Scientific Officer at BERG oversees all research & development activities. He is the co-inventor and co-architect of the BERG Interrogative Biology® technology and leads the implementation of scientific strategies and overall operations of the multifunctional integrated scientific program intersecting science and technology. He is responsible for developing strategies for rapid validation of preclinical and translation into clinical development and beyond of drug targets, therapeutics and biomarkers in the areas of cancer, cardiovascular and metabolic diseases, neurological diseases and other area(s) of BERG focus. Dr. Sarangarajan’s education as a pharmacist and his diversity in graduate training provided the scientific acumen and knowledge base for diligent implementation of the fundamental tenets underlying the BERG Interrogative Biology® platform and the appropriate translation of its outputs in creation of the diverse BERG program pipeline. At the Massachusetts College of Pharmacy and Health Sciences (MCPHS), he oversaw the implementation of an integrated biological sciences program that intersected the basic sciences to clinical outcomes within the pharmacy curriculum. The transition to BERG provided Dr. Sarangarajan the opportunity to translate the concepts of study of integrating biological systems to drug discovery and development. Dr. Sarangarajan has numerous US and international pending patent applications, covering areas of discovery platform, cancer, metabolic diseases, diabetes, obesity and diagnostics. He has published extensively and has presented his research in national and international medical and scientific meetings. He co-authored and co-edited Cellular Respiration and Carcinogenesis, a first of its kind treatise on the role of mitochondrial function and metabolic network regulation in the etiology of cancer as it pertains to the seminal observations made by Otto Warburg. Dr. Sarangarajan is a member of numerous professional organizations and has served in various capacities including the New England Society of Cosmetic Chemists, the Society of Toxicology, American Society for Pharmacology & Experimental Therapeutics, American Association of Colleges of Pharmacy and has been a reviewer for many scientific journals in the areas of pharmacology & toxicology. Dr. Sarangarajan received his B.S. in Pharmacy from Maharaja Sayajirao University (India) and a Ph.D. in Pharmaceutical Sciences from the University of Cincinnati College of Pharmacy. He received post-doctoral training at the University of Cincinnati Children’s Hospital Research Foundation and Department of Dermatology prior to moving to MCPHS.

Day One

29th March 2017

09.00 | Can an Evolving Appreciation of Systems Biology Finally Result in that Universal Companion Diagnostic?

Manuel Silva
Director Histopathology, Global Clinical Biomarkers
& Companion Diagnostics, Merck KGaA

Manuel’s most recent position was Lab Head Non-Clinical Safety & Investigative Pathology, Roche Penzberg Innovation Centre, Penzberg, Germany. In this global role he set-up a pathology Lab providing strategic operational and scientific expertise performing safety preclinical tissue-based analysis assessing biologics and biomarkers for oncology, ophthalmology and neuroscience. Manuel was also Histopathology Head & Investigator II, Biomarkers Unit, Novartis Institute for Biomedical Research, Horsham, UK. Working in immunology of respiratory disorders like COPD, asthma, cystic fibrosis pulmonary fibrosis and hypertension, he developed and managed a research Lab performing tissue-based biomarkers using automated immunostaining and digital image analysis. Manuel has extensive academic research experience as a post-doctoral fellow working in the field of gastrointestinal mucosal immunology investigating the pathophysiology of inflammation in Crohn’s disease, Celiac disease, and irritable bowel syndrome at the University of Montreal, Montreal, and McMaster University, Hamilton, Canada. He lead and developed projects in innate immunity, epithelial barrier function, and intestinal microbiota having numerous publications in various high-impact journals. Manuel obtained first a Biochemistry degree and then completed a Medical Doctorate and General Medicine Residency at the Pontifical Catholic University of Chile, Santiago, Chile. Prior starting with his biomedical research career, Manuel worked for 3 years proving Health Care as a General Practitioner in Chile.

Day Two

30th March 2017

16.30 | The Evolving Role of Digital Biomarkers, Diagnostics & Pathology

Heather Stevens
Head, Global Companion Diagnostics Strategy
Roche Pharmaceuticals

Heather Stevens is Head, Global Companion Diagnostics Strategy for Roche Pharmaceuticals. Her team is responsible for developing and implementing commercialization strategies for all Companion Diagnostics by ensuring strategic alignment and launch readiness across Pharma and Diagnostics. Heather was previously at Novartis, where she established the strategy for a new Commercial Center of Excellence for Diagnostics within the Pharmaceuticals (General Medicines) division.  Previously, was Regional Head of Sales EMEA for Novartis Diagnostics, leading a large geographic expansion in the Middle East and Eastern Europe.  Prior to that, she led a cross-functional team to commercialize a traditional and molecular immuno-hematology portfolio in the US and Canada. Heather began her career as a consultant at Health Strategies Group, a consultancy focused on US market access strategy for pharmaceuticals and biotech products.  Heather holds a Bachelors Degree in Human Biology and a Masters in Sociology from Stanford University, and an MBA and Masters in Public Health from UC Berkeley.

Day One

29th March 2017

12.15 | Panel Discussion: 4 Key Stakeholders – Aligned or Misaligned Expectations?

Luc Van Rompaey
Vice President, Translational Medicine

Luc Van Rompaey serves as VP Translational Medicine at argenx, an emerging biotech in the field of oncology and autoimmune diseases with a pre/clinical pipeline including 4 Phase II programs. He leads biomarker, animal modeling and translational studies for the pre/clinical programs. Before joining argenx, Luc played a pivotal role in the development of Galapagos NV, joining soon after its inception. He made important contributions to the successful implementation of the functional genomics platform, discovering novel osteoporosis targets that were outlicensed to Procter&Gamble, Wyeth and Eli Lilly.  He was instrumental in transitioning Galapagos’ operations from target to drug discovery research. He started the JAK inhibitor research program, led the discovery and contributed to the Development of the JAK1 inhibitor GLPG0634, currently initiating Phase 3 trials in rheumatoid arthritis and Crohn’s disease. He served on alliance management teams for drug discovery collaborations with GSK, Eli Lilly and Servier in the fields of osteoarthritis, immunity & inflammation, osteoporosis and oncology. Prior to joining Galapagos he performed postdoctoral research in tumor biology in St Jude Children’s Research Hospital (US) and Leuven University (Belgium).

Miro Venturi
Global Head, Diagnostics, Biomarkers

After receiving his PhD from the Max-Planck Institute of Biophysics in Frankfurt, Miro specialized in molecular medicine, virology and immunology at the National Institutes of Health, Bethesda, USA. In 2002, Miro joined the pharmaceutical industry as a Biomarker Laboratory Head and project team representative at Pharmacia Corp (later Pfizer Inc.) at the Oncology R&D site located in Nerviano, Italy. In this role, he initially established the biomarker laboratories and actively contributed to the development of numerous oncology programs focusing on small molecular weight kinase inhibitors, including the early development of sunitinib (Sutent) as well as research and exploratory biomarker strategies for several preclinical programs, from lead optimization until PoC clinical studies. In 2005, Miro was invited to join the faculty of the University “Vita Salute San Raffaele” in Milan as Adjunct Professor of preclinical and early clinical development of biopharmaceuticals. In 2007 Miro moved to Novartis as Divisional Head in Biomarker Development, supervising a team of scientists developing assays and supporting project teams in the realization of personalized medicine strategies across the portfolio, with a focus on biologics and oncology programs. His team has contributed to the development of nilotinib (Tasigna) and early programs in both solid tumors and hematological malignancies. Since 2009, Miro joined Roche Oncology where he has contributed the biomarker and personalized medicine strategies and directed the execution for global drug development programs with companion diagnostics, including the development and approval of Perjeta in breast cancer. In 2011, he was appointed Site Head for Oncology Biomarkers within the DTA Oncology Dept, under the leadership of William Pao, and based in Penzberg, Germany. Miro has then been appointed Global Head of Diagnostics Biomarkers at Hoffmann-la Roche and is based at the Company´s headquarters in Basel. Miro has contributed to several drug research and scientific development projects and published in a number of relevant scientific journals, including Nature, Cell, PNAS and others

Day One

29th March 2017

08.20 | Chair’s Opening Remarks

Birgitte Volck
Senior Vice President & Head of Rare Diseases R&D

Birgitte holds the role of Senior Vice President and Head of R&D Rare Diseases at GSK. She has previously held positions at Sobi, Amgen, Genzyme and Pharmexa. She gained PhD from the University of Copenhagen.  

Day Two

30th March 2017

10.30 | Precision Medicine Advances in Rare Disease Indications

Diagnostic & Technology Experts

Steve Anderson
Chief Scientific Officer
Covance, Inc.

Day Two

30th March 2017

17.00 | Chair’s Closing Remarks

08.50 | Chair’s Opening Remarks

Wesley Buckingham
Senior Manager, Diagnostic Product Development
Nanostring Technologies

Day One

29th March 2017

08.30 | From Biomarker Signature to a Deployed Diagnostic: The Benefits of Starting in an Early Phase with a Robust Scalable Solution

Jordan Clark
Managing Director
Labceutics, Diaceutics Group

Jordan has academic and professional qualifications in Biomedical and Clinical  Sciences and work experience as a Biomedical Scientist in Histopathology, Blood sciences and Microbiology, Clinical Scientist in Hematology and EQA scientist at UKNEQAS LI.  Jordan’s fields of expertise include pathology, especially molecular hemato-oncology. Jordan is responsible for the delivery of all Labceutics projects ensuring clients needs are met and surpassed.

Berwyn Clarke
PBD Biotech Limited

Dr Clarke has worked in the pharmaceutical and diagnostics industry for the last 31 years occupying senior management positions and Board level appointments. His background is primarily scientific but he is now a commercially focused entrepreneur with multiple corporate appointments. Dr Clarke is a specialist in personalized medicine, companion diagnostics and the application of novel diagnostics both to central laboratory and point-of-care utilities. He founded diagnostics company, Lab21, in 2005 and is now operating with a portfolio of new and established companies who have products at various stages of commercialisation. Originally a biochemist with a PhD in Medical Genetics, Dr Clarke also has significant experience in antiviral drug development and human vaccine programmes. Dr Clarke is currently CEO of PBD Biotech Ltd, Entrepreneur-in-Residence at Cardiff University and Executive Chairman of NALIA Biosystems and Iceni Diagnostics Limited.  

Jonathan Frampton
Diagnostics Strategic Alliance

Colin Hill
Senior Vice President Commercial Operations

Day One

29th March 2017

12.15 | Panel Discussion: 4 Key Stakeholders – Aligned or Misaligned Expectations?

Bob Holt
Companion Diagnostic Development Manager

Day One

29th March 2017

10.45 | Using LDTs to Streamline CDx Development

Jacob Hunter
Director, Companion Diagnostics Partnering
Ventana Medical Systems

Day One

29th March 2017

09.30 | Providing the Perfect Solutions for Your Biomarker Continuum

Bruce Jordan
Vice President, International Business Leader, Companion Diagnostics
Roche Diagnostics

Dr. Bruce W.M. Jordan joined the Roche Pharmaceuticals Herceptin team in Basel in 2005, leading the HER2 Testing/Companion Diagnostics (CDx) activities. Since January 2013 he is International Business Leader - Companion Diagnostics at Roche Professional Diagnostics HQ in Rotkreuz. Bruce has worked on CDx development & commercialization out of both the Pharmaceuticals and Diagnostics Divisions, across Neurology, Immunology and Oncology. Bruce trained in Laboratory Medicine, graduating from the University of Portsmouth U.K. in 1994 with a BSc. (Hons.) Biomedical Sciences, subsequently gaining State Registration in Haematology and Transfusion Medicine at Southampton General Hospital. He has also worked at the Royal Marsden Hospital, London, and has a Ph.D. in cancer research from the University of Würzburg in Germany. Today, Bruce also represents the diagnostics industry as a Corporate Representative at the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and is a Fellow of the Institute of Biomedical Sciences (FIBMS) in the U.K.

Day One

29th March 2017

09.30 | Providing the Perfect Solutions for Your Biomarker Continuum

Seamus Kearney
CEO & Principal Consultant
ARC Regulatory

Brian Kelly
Global Director, Diagnostic Partnering
Thermo Fisher Scientific

Peter Kerr
Vice President, Companion Diagnostic Development
Almac Diagnostics

Dr Peter Kerr (VP CDx Development) leads the project management and product development activities at Almac Diagnostics, working with the pharmaceutical industry on the discovery, development and delivery of biomarker services, often as part of a companion diagnostic pipeline. This team is also responsible for Almac Diagnostics’ product development pipeline of proprietary prognostic and predictive biomarkers and diagnostics. Peter studied at Cambridge University before performing postgraduate work at Edinburgh and Glasgow Universities leading to a Ph.D.  He worked on the functions of BRCA1 and BRCA2 genes at the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London, before establishing and managing a microarray facility there.  He then worked as a Programme Manager with the NCRI Informatics Initiative in London, before joining Almac Diagnostics in 2006.  

Karina Kulangara
CDx Development Manager
Agilent Technologies

Karina oversees product development teams and is responsible for a portion of the portfolio of complex and business critical Companion Diagnostics projects. She has overall responsibility for resource allocation, directing, executing and coordinating designated projects between Dako/Agilent and its pharma partners and for meeting all Design Control requirements and Product Specifications.

Ivan Malagurski
Global Director & International Product Manager Personalised
Healthcare Solutions, Roche Diagnostics

Day Two

30th March 2017

09.00 | Advances in Non-Oncology Personalised Healthcare Solutions: Successful Model in Fertility Treatment

Keith Page
Director Scientific Development
Asterand Bioscience Inc.

Suso Platero
Executive Director, Immuno-Oncology & Precision Medicine Oncology Leader
Covance, Inc.

Jessica Riley
Senior Director, Business Development, Pharma Partnerships
Leica Biosystems

Jessica Riley, PhD is Senior Dir, Business Development at Leica Biosystems. She joined the company 4 years ago to help establish and grow the CDx business unit by leveraging her experience of the last decade working in the whole continuum of CDx care for patients. Following her work at St James’s University Hospital where she initiated the first NGS BrCa screening test in the UK, she joined DxS Ltd (now a Qiagen company) in Manchester where she was part of the team who developed and launched the first KRAS and EGFR global CDx PCR devices in partnership with a number of Pharmaceutical companies, pioneering the precision medicine industry.  She moved to Boston Massachusetts to join start up company PrimeraDx, a platform company enabling highly multiplex PCR tests for precision medicine applications. Following her time at PrimeraDx (subsequently a Qiagen company), she joined Leica (a Danaher company) where together with her team, envisions growing a center of excellence for CDx amongst all Danaher operating companies to provide a comprehensive portfolio of technologies to realize  multi-modality precision medicine capabilities on a global scale

Vishal Sikri
Vice President, Commercial Operations
Sysmex Inostics

John Simmons
Director, Translational Science & Diagnostics
Personal Genome Diagnostics

John Simmons, PhD is the Director of Translational Science and Diagnostics at PGDx. In this role, John focuses broadly on scientific strategy and biomarker discovery and diagnostics development partnerships with pharma/biotech.  Previously, John was at the National Cancer Institute where his research focused on identifying novel therapeutic strategies for multiple myeloma through chemical genomic approaches with a particular focus on drug combinations. He received his undergraduate degree in Biology with honors from American University and Ph.D. in Tumor Biology from Georgetown University as part of the NIH Graduate Partnership Program. As a post-doctoral fellow, he received the Multiple Myeloma Research Foundation (MMRF) Research Fellow award to support his work in developing systems-level approaches for drug combination identification and prioritization.

Tom Turi
Vice President, Companion Diagnostics
Covance, Inc.

Thomas Turi, Ph.D. is Vice President Companion Diagnostics for Covance Central Laboratory Services. He joined Covance in 2008 to establish the Biomarker Center of Excellence and was integral to the acquisition of the Covance Genomics Laboratory and the formation of Discovery and Translational Services. He is currently responsible for Covance’s Companion Diagnostics efforts.  Prior to Covance, Dr. Turi spent fifteen years in the pharmaceutical industry, where he held a broad array of scientific leadership positions of increasing responsibility. Most recently he served as the Senior Director of Translational Biomarkers and Mechanistic Biology at Pfizer. In addition to his current responsibilities, Dr. Turi has served on the Board of Trustees for The Life Sciences Foundation and is a member of the Global Health Research Roundtable of the Indiana Clinical and Translational Sciences Institute.  He has previously served on the Board of Directors for Caprion Proteomics and led several external partnerships including those with Rules Based Medicine, Celera, Incyte, and Affymetrix. He has also served on grant and program project review boards for NASA’s Section for Biotechnology and Tissue Engineering. Dr. Turi received dual bachelors degrees in Biochemistry and Chemistry from the University of Illinois at Urbana-Champaign and his doctorate in Molecular Genetics from the University of Cincinnati College of Medicine. He completed postdoctoral training at the Yale University School of Medicine applying molecular genetic techniques to investigate the mechanisms of protein transport.    

Day Two

30th March 2017

10.00 | CDx Beyond Oncology

Academics, Advocates & Associations

Rajesh Chopra
DirectorCancer Research UK, Cancer Therapeutics Unit, Head,
Division of Cancer Therapeutics, The Institute for Cancer Research

Denis Horgan
Executive Director
European Alliance for Personalised Medicine

Denis Horgan is the Executive Director of the European Alliance for Personalised Medicine (EAPM). Denis’s background blends extensive expertise in health policy and issue advocacy with a unique understanding of how civil society interact with today’s political arena at the European and Member State level. Prior to working with the EAPM, Denis worked with the European Cancer Patient Coalition and in the European Parliament on broad array of health issue relating to the pharmaceutical area and patient issues and in international NGOs on health development projects in Afghanistan, Mexico and Palestine. Over the course of his career, Denis has developed numerous public affairs initiatives in the areas of advocacy, social marketing, policy support and launch, policy development and media relations. As a senior policy affairs manager, he has actively been involved in coalition building, grassroots advocacy, conferences development and development of policy platforms to support access to reimbursement/treatment at the political level and with institutions/bodies.Belgium.

Day Two

30th March 2017

16.00 | Enhancing the Adoption of Precision Medicines: Patient Advocacy & Healthcare Education

Jacqueline Hall
Executive Director

Jacqueline has pursued a career path in diagnostics with diverse experience from translational research and data analysis, to clinical trials, research infrastructure and the transfer to the clinic with in external quality assessment of biomarker testing. After completing a bioinformatics analysing high throughput DNA methylation data she completed a postdoc at McGill University, Canada, on the breast cancer microenvironment. From there, Jacqueline worked in clinical trials as Head of the Translational Research Unit at the EORTC where she was invovled in implementation of diagnostics and translational research in pan European, molecularly-targeted, clinical studies. Jacqueline then helped to establish the IQN Path ASBL, a not for profit association focussed on quality implementation of biomarker testing in the clinic, where she is currently the Executive Director. Currently, IQN Path has a membership of 11 EQA providers and 12 corporate entities worldwide. Jacqueline is also an Honoary Senior Lecturer at Imperial College London.    

Yong-Jie Lu
Reader in Medical Oncology, Barts Cancer Institute,
Queen Mary University of London, speaking on behalf of ANGLE plc

Dr. Yong-Jie Lu is a Reader in Medical Oncology at Barts Cancer Institute, The Barts and London School of Medicine and Dentistry, Queen Mary University of London. He has completed his MD in 1992 and PhD (at Cancer Institute/Hospital, CAMS) in 1995. He did his postdoctoral studies in Cancer Genetics at Institute of Cancer Research, London and set up his own research team for male urological cancer genetic and biomarker studies at Barts Cancer institute, Queen Mary University of London in 2003. The mission of his research is to identify genetic alterations and genes significance in influencing the development, progression and therapeutic response of human cancer. His research is currently focusing on biomarker development and ‘liquid biopsy’, in particular in the area of circulating tumour cells. He has published more than 100 papers in reputed journals and has recently filled two patent applications. He has been serving as editorial board members for a number of international scientific journals.  

Fay McCracken
Adviser, Office for Market Access & Technology Appraisals
National Institute for Health & Clinical Excellence (NICE)

Day One

29th March 2017

12.15 | Panel Discussion: 4 Key Stakeholders – Aligned or Misaligned Expectations?

11.45 | The NICE Perspective on Precision Medicine & CDx Market Access

Simon Patton
The European Molecular Genetics Quality Network (EMQN)

Simon Patton, PhD is Director of the European Molecular Genetics Quality Network (EMQN) – the global leader in the provision of External Quality Assessment (EQA) schemes to diagnostic laboratories in the fields of genetics and pathology.  He trained at the University of Liverpool in marine biology, before doing his doctorate in Genetics at the University of Cambridge. He is currently at Central Manchester University Hospitals NHS Foundation Trust.  Simon’s work has focussed on global improvement in the standards and quality of diagnostic laboratory testing – a field that he has worked in since 1999 through his involvement with the EMQN.  

Christian Rolfo
Associate Professor & Head of Phase I- Early Clinical Trials Unit
Antwerp University Hospital

Christian studied at the National University of Córdoba, graduating from medical school in 1996. In 1998 he began his studies at the University of Milan, Italy. He got a scholarship for a project in Breast Cancer with Prof. Luca Gianni at National Cancer Institute of Milan for more than six years, He trained with Drs. Licitra and Casali. During this period he was dealing with caring and Research Protocols Phase I, II and III, under the direction of Prof. Gianni. Obtained the European Oncology Board certication in 2003 thesis of Phase I in Breast Cancer. he is also a Doctor of Medicine and Surgery at the University of Catania, Italy. In 2004 he moved to Mallorca, Spain, Clinica Rotger until September 2012. It is here where he began his work in the Spanish Group for Lung Cancer, with Prof. Rosell. In 2009 obtained the PhD degree and Doctor Europaeus in Clinical and Experimental Oncol Res with cum laude from the University of Palermo, for the thesis: Relationship Between metabolic activity (SUV max) by 18-FDG PET and Histology, stage, EGFR mutations and survival in NSCLC, tutor Profs.Rosell and Russo. From October 2012 is Senior Staff Member in the Department of Oncology as Assoc Professor at the University Hospital Antwerp, Belgium, headed by Prof. Marc Peeters . He completed his training in Phase I program at MD Anderson, USA with Prof. Hong. He published in various journals including New England Journal of Medicine, Translational oncology,etc . Currently he is Head of Phase I - Early Clinical Trials Unit , Director of Clinical Trails Management Program as well. He is focus on Clinical Research, Drug Development and Resistance. He is actively working in Research program of Liquid Biopsies in Lung Cancer, specifically in exosomes isolation and circulating tumor DNA. He is part of membership Board of IALSC and others AACR, EACR, ESMO, ASCO. Is guest professor at Univ. Palermo and director of Fellowship in Drug development Belgium.

Anthony Whetton
Professor of Cancer Cell Biology, Director, Stoller Biomarker Discovery Centre,
Director, Manchester Precision Medicine Institute, University of Manchester

Professor Tony Whetton is Director of the Stoller Centre for Biomarker Discovery and also the Manchester Precision Medicine Institute. He is also principal investigator of the Bloodwise Mass Spectrometry programme based at the Wolfson Molecular Imaging Centre, Christie Hospital. Tony joined the School of Medicine at Manchester University in 2003 as Professor of Cancer Cell Biology, based at the Christie Hospital. Here he established a state of the art biological mass spectrometry facility for stem cell and cancer research. This platform has been extended into biomarker research for precision medicine in recent years. In his leukaemia research Tony is currently systematically defining the downstream proteomic and phosphoproteomic effects of the protein tyrosine kinases associated with myeloproliferative disorders and myeloid leukaemias to discover common mechanisms for leukaemic transformation and thus new drug targets. This has lead to a new approach to extinguish chronic myeloid leukaemia stem cells. He has built a new £3 million laboratory to house the Stoller Biomarker Discovery Centre which has £25 million of funding to date and opened in June 2016. As Director of the Manchester Precision Medicine Institute Tony Whetton leads on enabling University of Manchester researchers, clinicians and industry to work together for improving clinical outcomes.